Fmr LLC Buys 181,703 Shares of Amgen Inc. (NASDAQ:AMGN)

Fmr LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 4.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,247,304 shares of the medical research company’s stock after acquiring an additional 181,703 shares during the period. Fmr LLC owned 0.79% of Amgen worth $1,368,524,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter valued at $25,000. Strategic Financial Concepts LLC bought a new stake in Amgen in the second quarter valued at $26,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the second quarter valued at $30,000. nVerses Capital LLC bought a new stake in Amgen in the second quarter valued at $31,000. Finally, Bbjs Financial Advisors LLC bought a new stake in Amgen in the second quarter valued at $33,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AMGN shares. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Bank of America raised their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Citigroup started coverage on Amgen in a research report on Thursday, November 14th. They set a “neutral” rating and a $335.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Oppenheimer reissued an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $333.57.

Amgen Trading Down 4.8 %

Amgen stock opened at $280.01 on Wednesday. The business has a 50-day simple moving average of $314.64 and a two-hundred day simple moving average of $317.84. The company has a market cap of $150.51 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.63 and a beta of 0.60. Amgen Inc. has a 52-week low of $257.80 and a 52-week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the company posted $4.96 EPS. Analysts predict that Amgen Inc. will post 19.52 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.21%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.